Connecting biopharmas with the right preclinical cancer models and CRO partners

Cancer Models Forum

Posted by Justyna, June 2020

3 features to help you find a reliable cancer model with the right molecular phenotype

To succeed at bringing effective cancer therapies to market today, you need to find a reliable preclinical model that matches the molecular phenotype of the cancer you are targeting. But since every cancer has a unique molecular phenotype and there are hundreds of preclinical oncology CROs with 10,000s of translational cancer models based on different technologies, this isn't as straightforward as it sounds.

At Repositive, we're committed to helping pharma and biotech researchers find the most suitable translational model for their study via our Cancer Models Platform and Cancer Models Scout service.

Over the last couple of months, we’ve been busy enhancing the user experience of our platform based on valuable feedback from pharma and biotech researchers. In this blog post, I'll be sharing a summary of this user feedback and a round-up of the new features that we’ve recently added to our platform in response to this.

Interested to share your thoughts on our platform or be part of its future development?

Get in touch via email at or via our platform’s online chat. We’d love to hear from you!

1. Drug treatment filters

Through helping a variety of biopharma companies with their preclinical model searches via our Cancer Models Platform and Cancer Model Scout service, we realised just how important drug treatment data is when selecting a model. In fact, around 40% of all our model requests require drug treatment data and most researchers often need a combination of both molecular and clinical data in order to make a more informed decision. Therefore, we decided to add drug treatment data for both patient and model responses to our platform.

Our new drug treatment filter allows you to browse more than 2,633 RECIST-standardised data points. This can be done by simply choosing your drug treatment type from the dropdown menu - you can then refine the returned model list further by selecting a desired treatment response, such as 'partial response'.

Learn more about our new drug treatment filters in this blog post.

2. Live chat

When browsing our platform, many researchers have queries about accessing additional model data, such as growth curves, whole-exome sequencing and histology images, or being connected with the CRO offering the model of interest. We want to make sure that you have on-hand support from our customer success team when searching for your preclinical cancer models. As such, we have added a live chat function to our platform.

You can find the chat panel on the bottom right-hand corner of your screen when browsing cancer models on our platform. The live chat function is available Monday-Friday 9am-5pm GMT/BST and has a variety of channels to ensure your specific query is directed to the right member of our team.

Find out more about our new live chat here.

3. Dynamic filters

With over 280 cancer subtypes, 23,000 genetic mutations and 160 model/patient treatments to filter our directory by, it’s perhaps not surprising that our users wanted an easier way to narrow down their model selection. Consequently, we’ve added dynamic filters to our platform.

Now, by simply selecting your desired primary site, the model subtypes available in our directory will be automatically displayed in the relevant dropdown filter menu, making it easier for you to search through over 280 cancer subtypes in the free version of our platform to return only models that match your chosen primary site.

For our enterprise users, this new feature also extends to our gene mutation and drug treatment filters, making it quick and simple to search over 23,000 gene mutations and more than 160 model/patient treatments in our directory.

Try our dynamic filters on our Cancer Models Platform today.


We hope you enjoyed reading about the new features on our platform and why we decided to prioritise these in response to user feedback. While you are here, I wanted to reiterate the importance of your input in the development of our Cancer Model Platform. We have been in constant contact with the preclinical oncology community since we launched our platform to discuss key painpoints, potential solutions and feedback on new features. Being able to gather more insight into the specific challenges, hurdles and goals that pharma and biotechs face when trying to source a cancer model with the right molecular phenotype is essential. With this constant discovery and feedback process underpinning our agile development pipeline, we can continue to iterate and build the best platform to support your model searches.

Stay tuned for more features coming soon!

Would you like to be part of our platform development?

Drop us an email at or contact us via the online chat on our platform. We’d love to hear your feedback!

Image credit: You X Ventures on Unsplash